Introduction: Viral kinetics has proved useful
INTRODUCTION
Long-term suppression of serum hepatitis B virus (HBV) DNA is likely to reduce progression to cirrhosis and hepatic decompensation and to decrease the risk of hepatocellular carcinoma. Therefore, the primary goal of therapy for chronic hepatitis B (CHB) is suppression of viral replication [1] [2] [3] .
No currently available single medication is able to achieve both potent HBV DNA suppression and high rates of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance. Therefore, drug combination, which is a therapeutic strategy that has been shown to be successful to reduce viral resistance in human immunodeficiency virus (HIV) therapy, attracted some interest in CHB management. In initial trials evaluating the combination of pegylated interferon (PegIFN) and lamivudine, a slightly enhanced viral suppression and lower resistance rates were observed with the combination compared with either drug alone [4] [5] [6] . A clear advantage of the combination over each monotherapy treatment for long-term outcomes such as HBeAg or
HBsAg seroconversion was not demonstrated. In vitro, slightly synergistic effects to additive effects have been suggested for some combinations of nucleos(t)ides [7] [8] [9] .
Telbivudine demonstrated additive to weakly synergistic anti-HBV activity in vitro when combined with tenofovir or entecavir; there was no evidence of cytotoxicity [10] . Previously, mathematical modeling of early HBV kinetics has been used to examine the efficacy of combination therapy with dual nucleos(t)ide analogs, namely famciclovir with lamivudine or adefovir with emtricitabine [11, 12] .
Learning from these studies, the current investigation was designed to examine the effect of a combination of more potent antiviral agents, telbivudine and tenofovir disoproxil for chronic HBV infection. Unlike previous studies [13] [14] [15] [16] , immunotolerant patients were studied so as to avoid the interference of host immune system on the understanding of whether there is any true synergistic effect. These studies included lamivudine in the combination and demonstrated limited clinical benefit over monotherapy for virological endpoints [17] [18] [19] . Analysis of resistance demonstrated that combination of lamivudine with another nucleoside or PegIFN was associated with lower resistance rates to lamivudine [5, 6, 18, 19 
HBV DNA Quantification
Serum of patients was collected for HBV DNA measurement at baseline and at all scheduled visits. Serum HBV DNA determinations were conducted at a central laboratory using COBAS TaqMan Ò HBV DNA assay, which utilizes the real-time polymerase chain reaction.
Viral Kinetics
Viral kinetic parameters were estimated with a biphasic mathematical model of HBV DNA using compartments of free virus, infected cells and uninfected target cells [14, 22, 23] . The differential equation system of the underlying biphasic model of viral kinetics was as follows:
where V denotes serum viral load, I productively infected cells, e the efficiency factor of blocking virus production, p the viral production rate, c the viral clearance rate, g the efficiency factor of blocking de novo infection, b the de novo infection rate, T g comprises all infected and uninfected target cells, and d the rate of infected cell loss [13, 14, 22] .
Maximum-likelihood estimation methods
for the viral kinetic parameters c, e, and d entailed the fitting of a nonlinear differential equation system via the least-squares approach from the serum HBV DNA data collected during the treatment period. In addition, g = 0.5 was used as in previous analyses and the viral kinetic parameters for p and b can be derived from the others when assuming a steady state before treatment starts. MATLAB (MathWorks Inc., Natick, MA, USA) routines were used to calculate these estimates.
Safety Assessment
Vital signs, physical examination and laboratory parameters were collected at screening, baseline and at all scheduled visits.
All adverse events and serious adverse events were reported with their severity and relationship to the study drug.
Statistical Analysis
All efficacy assessments were performed on the intent-to-treat population, which consisted of all patients who had been randomized and had received at least one dose of study drug. Kruskal-Wallis test and nonparametric WaldWolfowitz test were used to compare the data and to assess data variability, respectively. The safety population consisted of patients that had been randomized and had taken at least one dose of the study drug. All statistical tests were bilateral with a 0.05 alpha level of significance.
RESULTS

Patient Disposition
Forty-seven patients met the inclusion/ exclusion criteria ( 
HBV DNA Decline
The mean HBV DNA reduction in the three treatment arms was almost identical (Fig. 1) . As soon as Day 2, the mean decrease of HBV DNA level was -0.53 log 10 copies/mL in telbivudine group, -0.58 log 10 copies/mL in tenofovir group and -0.54 log 10 copies/mL in combination group.
Since Week 3, the mean (SD) HBV DNA reduction was numerically higher in the combination group compared to the monotherapy groups: telbivudine plus ALT Alanine aminotransferase, HBeAg Hepatitis B e antigen, HBV Hepatitis B virus, SD Standard deviation tenofovir, -3.1 (0.7) log 10 copies/mL; as compared to -2.9 (0.9) log 10 copies/mL in telbivudine monotherapy group and -2.9 (0.6) log 10 copies/mL in tenofovir monotherapy group. At Week 12, the greater HBV DNA reduction in the combination group persisted with mean (SD) decrease of -4.4 (1.0) log 10 copies/mL in the combination group compared to -3.9 (0.9) log 10 copies/mL in telbivudine group and -4.2 (0.7) log 10 copies/mL in tenofovir group (Fig. 1) . Combination treatment provided slightly more decrease of HBV DNA copies from baseline to Week 12 than telbivudine or tenofovir. However, the differences between the three groups did not achieve statistical significance.
One female patient of 40 years of age in the combination group achieved undetectable serum HBV DNA (\169 copies/mL) and became HBeAg negative at Week 12. This patient had a medical history of compensated CHB and at baseline HBV DNA level was 28,750,800 copies/mL and ALT level was 61 IU/L.
Viral Kinetics
The data supported the biphasic model for viral kinetics and no patient showed deviation from the biphasic pattern. There were no significant differences between the three groups in terms of viral clearance rate per day (parameter c: 0.97 for telbivudine, 1.02 for tenofovir, and 0.88 for telbivudine plus tenofovir) or infected cell loss rate per day (parameter d: 0.04, 0.05, and 0.05, respectively; Table 2 ).
Efficiency in blocking viral production (e parameter) was not significantly different between the two monotherapy groups (median at 99.7% in telbivudine group and 99.4% in Table 2 ). This viral kinetics parameter was more homogeneous in the combination treatment group than in the monotherapy groups: mean (SD), 99.1% (0.8%) and 98.8% (1.6%), respectively (Wald-Wolfowitz test; P = 0.038). Figure 2 shows that first-phase log decay of virus was overall comparable in the three groups. Data in the telbivudine group showed a slightly higher median value compared to tenofovir monotherapy or combination treatment group. Furthermore, the minimum and maximum values of the combination treatment group were higher than the other treatment groups.
Safety
All treatments were well tolerated and no serious adverse event was reported during the study. The adverse events reported were expected for this study population and class of drug. Of the 46 patients in the safety population, 23 experienced adverse events (16 events in telbivudine, 14 in tenofovir, and 16 in as not suspected to be related to study drug by investigators. Adverse events reported to be related to study drug were dizziness (n = 1; drug combination), dyspepsia (n = 1; drug combination), nausea (n = 2; drug combination), upper abdominal pain (n = 1; tenofovir), and somnolence (n = 1; tenofovir).
Two muscle-related adverse events were reported. None were considered to be drug related. One was reported in the tenofovir group This viral kinetics study demonstrates that telbivudine and tenofovir have the same potency. Similar results were reported in a previous published study by Suh et al. [13] comparing telbivudine versus entecavir which showed similar potency between entecavir and telbivudine. The 12-week study by Suh et al. [13] in HBeAg-positive patients (with ALT C1.3 9 ULN) has shown equal potency in an analysis comparing the viral kinetics parameters with telbivudine (HBV DNA reduction, -6.6 ± 1.6 log 10 copies/mL) versus entecavir (-6.5 ± 1.5 log 10 copies/mL) treatment.
There were no significant differences between groups for mean values of viral clearance by day, loss of infected cells per day or efficiency of blocking viral production.
Consistent with this previous study, we report that the HBV DNA decrease was evident as soon as Day 2 after treatment initiation and was sustained during the 12-week treatment. The mean estimate of efficiency in blocking viral production (99.7%) was also consistent with the mean estimate of efficiency reported by Suh et al. [13] (99.1%).
Another study comparing telbivudine and entecavir for early response has been reported by Shi et al. [29] in HBeAg-positive patients. This study confirmed earlier results
showing no difference in the mean reduction in HBV DNA levels between the treatment groups (-5.27 log 10 copies/mL for telbivudine and -5.36 log 10 copies/mL for entecavir) [29] . Of interest, Shi et al. [29] have studied the relationship between the early and profound suppression of HBV DNA and the HBeAg seroconversion rate. These authors observed that, despite that HBeAg seroconversion is usually a rare event during the first 3 months of treatment with nucleos(t)ide treatment, higher rates of HBeAg seroconversion were achieved in telbivudine-treated patients compared to entecavir-treated patients at Week 12 (20% vs. 5%, respectively; P = 0.043) and Week 24 (27.5% vs. 17.5%; P [ 0.05) [29] . To explain this finding, an additional mechanism of action for telbivudine in the suppression of HBV replication has been suggested. Preliminary results suggest that telbivudine could exert antiviral effect not only directly by inhibiting viral replication, but also by stimulating the host immune system [30] [31] [32] .
Further studies are necessary to confirm that this effect on the immune system contributes to the high HBeAg seroconversion rates reported in long-term studies in telbivudine-treated HBeAg-positive patients [33] [34] [35] .
In the current study, both monotherapies had similar reduction [-4.374 
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